Putting Provenge in perspective.

نویسنده

Judd W Moul

چکیده

As a clinician and researcher in the prostate cancer field, I have been hearing that prostate cancer is “20 years behind” breast cancer now for the last 25 years! Who would have thought that poor ol’ prostate cancer would have an FDA-approved immunotherapy before breast cancer—and in fact, before any cancer![1] Furthermore, as a urologist, I am proud that a urologist is at the heart and soul of this advance, serving as the CEO of Dendreon, the company that has developed and commercialized sipuleucel-T (Provenge). Much has been written about sipuleucel-T over the last decade—and particularly over the last several years, since it was initially rebuffed by the FDA and then approved in May 2010.[2-5] Drs. Garcia and Dreicer have done an outstanding job of describing the development of sipuleucel-T, the other vaccines/immunotherapy approaches that have been developed for use in advanced prostate cancer, and the phase III results of the pivotal IMPACT trial that resulted in FDA approval for sipuleucel-T.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.

(1) Sipuleucel-T (Provenge) is an active cellular immunotherapy (therapeutic vaccine) that is designed to stimulate the patient's T-cells to recognize and attack prostate cancer cells that express prostatic acid phosphatase (PAP) antigen. (2) Sipuleucel-T demonstrated a survival benefit in men with advanced androgen-independent prostate cancer (AIPC), although this preliminary finding requires ...

متن کامل

Approval of provenge seen as first step for cancer treatment vaccines.

A decade in development, Dendreon’s prostate cancer vaccine, sipuleucelT (Provenge), has become the first therapeutic cancer vaccine to receive approval from the U.S. Food and Drug Administration. The FDA approved Provenge in April to treat metastatic castration (hormone)-resistant prostate cancer. In the phase III trial, known as IMPACT, patients taking Provenge had a 4.1-month median improvem...

متن کامل

CCR Drug Updates PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

Sipuleucel-T (PROVENGE; Dendreon) is the first therapeutic cancer vaccine to be approved by the U.S. Food and Drug Administration. In men who have metastatic castration-resistant prostate cancer with no or minimal symptoms, sipuleucel-T prolongs median survival by 4.1 months compared with results in those treated with placebo. At 3 years, the proportion of patients in the vaccine group who were...

متن کامل

رابطه‌‌ راهبردهای تنظیم شناختی هیجان با ایده‌پردازی خودکشی

The goal of current research was to assess the relationship between strategies for cognitive regulation of emotions and suicidal ideation. To do so, 120 Kharazmi University students (60 male and 60 female) were selected randomly and assessed by Cognitive Emotion Regulation Questionnaire (CERQ) and Beck Scale for Suicidal Ideation (BSSI). Results indicated that self-blame, rumination, catastroph...

متن کامل